The tumor suppressive miR-29 family of microRNAs is encoded by two clusters, miR-29b1~a and miR-29b2~c, and is regulated by several oncogenic and tumor suppressive stimuli. Here we investigated whether oncogenic MAPK hyperactivation regulates miR-29 abundance and how this signaling axis impacts melanoma development. Using mouse embryonic fibroblasts and human melanocytes, we found that oncogenic MAPK signaling stimulates p53-independent and p53-dependent transcription of pri-miR-29b1~a and pri-miR-29b2~c, respectively. Expression analyses revealed that while pri-miR-29a~b1 remains elevated, pri-miR-29b2~c levels decrease during melanoma progression. Using a rapid mouse modeling platform, we showed that inactivation of miR-29 in vivo accelerates the development of frank melanomas and decreases overall survival. We identified MAFG as a relevant miR-29 target that has oncogenic potential in melanocytes and is required for growth of melanoma cells. Our findings suggest that MAPK-driven miR-29 induction constitutes a tumor suppressive barrier by targeting MAFG, which is overcome by attenuation of miR-29b2~c expression.
INTRODUCTION
Malignant melanoma is an aggressive cancer that arises as a consequence of activation of proto-oncogenes, most commonly BRAF and NRAS. Despite the recent advances in melanoma therapy, most patients still succumb to the disease. A better understanding of the molecular biology of melanoma is needed to identify new therapeutic targets. Noncoding RNAs (ncRNAs) are critical regulators of cell biology whose alteration can lead to the development of cancer, including melanoma. ncRNAs can be classified based on their length into long non-coding RNAs (lncRNAs), those ncRNAs exceeding 200 nucleotides, and small non-coding RNAs, ranging from 18-200 nucleotides (Ponting et al. 2009; Djebali et al. 2012) . MicroRNAs (miRNAs) are a group of small non-coding RNAs that repress gene expression by binding to 3'UTRs of target mRNAs (Davis and Hata 2009 ). To date, various miRNAs have been reported to regulate the biology of melanoma cells (reviewed in (Wozniak et al. 2016; Fattore et al. 2017; Romano and Kwong 2017)) including miR-29a, for which tumor suppressive potential was recently described in in vitro ).
The miR-29 family is encoded by two clusters, miR-29b1~a and miR-29b2~c, located on chromosomes 7q32.2 and 1q32.2 in humans, respectively (Kriegel et al. 2012; Alizadeh et al. 2019) . Expression of the miR-29 clusters produces primary transcripts pri-miR-29b1~a and pri-miR-29b2~c, which are processed to generate three mature miRNAs, miR-29a, miR-29b, and miR-29c, that are highly conserved across species and share identical seed sequences (Kriegel et al. 2012) . miR-29 is considered a tumor suppressor miRNA given its ability to repress genes involved in proliferation and cell survival such as AKT3 (Ugalde et al. 2011; Wei et al. 2013) , DNMT3A/B (Nguyen et al. 2011 ), MCL1 (Mott et al. 2007) , and CDK6 (Zhao et al. 2010) . Over the last decade, miR-29 has emerged as a major regulatory hub that integrates signaling from potent oncogenes and tumor suppressors. Indeed, miR-29 expression is repressed by the oncogenes c-Myc, Hedgehog, and NF-B (Chang et al. 2008; Mott et al. 2010; Zhang et al. 2012b ). NRF2 was reported to stimulate or suppress miR-29 expression in different cell types (Kurinna et al. 2014; Shah et al. 2015) , and p53 promotes miR-29 expression when stimulated by aging or chronic DNA damage (Ugalde et al. 2011) .
In this study we tested if oncogenic MAPK signaling represses the expression of the tumor suppressive miR-29 family similar to other oncogenic pathways. Surprisingly, we found that miR-29b1~a expression is enhanced directly by the MAPK pathway and remains elevated in melanoma. Conversely, MAPK signaling requires p53 to promote miR-29b2~c expression, which enables attenuation of miR-29b2~c upon melanoma progression. Inactivation of miR-29 in a melanoma mouse model augmented tumor development. Finally, we identified MAFG as a miR-29 target whose de-repression may be important for melanoma progression.
RESULTS

Oncogenic BRAF and KRAS increase the abundance of mature miR-29 in mouse embryonic fibroblasts
The expression of miR-29 is repressed by several oncogenes -c-Myc, Hedgehog, NF-B, and, in certain contexts, NRF2 (Chang et al. 2008; Mott et al. 2010; Zhang et al. 2012b ; Kurinna et al. 2014; Shah et al. 2015 ) -while the tumor suppressor p53 promotes miR-29 expression in response to ageing and DNA damage stress (Ugalde et al. 2011) . We sought to examine if oncogenic BRAF and KRAS also lower miR-29 abundance. To this end, we ectopically expressed Braf V600E and Kras G12D in wildtype MEFs. Both oncogenes enhanced activation of the MAPK pathway, as indicated by an increase in phospho-ERK ( Figure 1A) . Unexpectedly, overexpression of Braf V600E or Kras G12D led to an increase of mature miR-29a, -29b, and -29c, an effect that was more pronounced in the Braf V600Eexpressing cells ( Figure 1A) . In MEFs, supraphysiological expression of Kras G12D enhances p53 activity compared to Kras G12D expressed at physiological levels (Tuveson et al. 2004) , which could explain the increase in miR-29 levels. As physiological expression of Braf V600E and Kras G12D provokes limited p53 activation, we examined miR-29 expression in MEFs carrying Cre-inducible endogenous Braf V600E and Kras G12D alleles (LSL-Braf V600E and LSL-Kras G12D ) (Jackson et al. 2001; Perna et al. 2015) . Adenoviral-Cre mediated activation of endogenous Braf V600E or Kras G12D induced the upregulation of miR-29a, -29b, and -29c ( Figure 1B and Supplementary Figure 1A) , indicating that physiological expression of these oncogenes also enhances the expression of the miR-29 family.
To determine if the regulation of miR-29 occurs at the transcriptional level, we assessed the expression of the miR-29b1~a and miR-29b2~c clusters using qPCR TaqMan probes 6 to detect the primary miRNA transcripts, pri-miR-29b1~a and pri-miR-29b2~c. Ectopic overexpression of oncogenic Braf V600E or Kras G12D increased both pri-miR-29b1~a and pri-miR-29b2~c ( Figure 1C ). Similarly, endogenous activation of Braf V600E or Kras G12D resulted in upregulation of both pri-miR-29b1~a and pri-miR-29b2~c ( Figure 1D and Supplementary Figure 1B) , indicating that oncogenic BRAF and KRAS indeed promote the transcription of both miR-29 clusters. MiR-29 may function as a melanoma tumor suppressor ) and the BRAF V600E mutation is found in over 50% of melanoma cases (Davies et al. 2002; Ascierto et al. 2012) . We therefore focused our further analyses on the regulation of miR-29 by oncogenic BRAF.
pri-miR-29b1~a and pri-miR-29b2~c are transcribed via the MAPK pathway and p53
To further assess if p53 plays a role in the regulation of miR-29 by oncogenic BRAF, we first ascertained that DNA damage-induced p53 activation enhances the expression of miR-29 in MEFs, as measured by mature miRNA qRT-PCR (Supplementary Figure 1C and 1D). We also tested if DNA damage increased miR-29 transcription and, surprisingly, found that Doxorubicin and Mitomycin C induced only the transcription of pri-miR-29b2~c ( Figure 2A ). This is at odds with the results obtained by mature miRNA qRT-PCRs where p53 activation increased expression of all three miR-29 family members. It is possible that the mature miR-29 qRT-PCR approach is unable to distinguish between miR-29a and miR-29c, which only differ in one nucleotide, as has been suggested previously (Kurinna et al. 2014) . Indeed, miR-29a and miR-29c Taqman assays were unable to distinguish between miR-29a and miR-29c mimics transfected into A375 melanoma cells (Supplementary Figure 1E ). Thus, the increased abundance of mature miR-29a upon DNA damage is most likely explained by elevated transcription of the highly homologous miR-29c family member.
The lack of pri-miR-29b1~a transcription upon p53 activation suggests that oncogenic Braf V600E -induced pri-miR-29b1~a expression is independent of p53. To further analyze the role of p53 in regulating Braf V600E -induced transcription of pri-miR-29b1~a and pri-miR-29b2~c we silenced p53 with a retroviral shRNA in LSL-Braf V600E MEFs (Supplementary Figure 1F ). Retroviral infection did not interfere with Braf V600E -induced pri-29b1~a and pri-miR-29b2~c expression (Supplementary Figure 1G ). As expected, induction of Braf V600E by adenoviral Cre failed to increase pri-miR-29b2~c expression in the absence of p53 ( Figure 2B ). By contrast, Braf V600E increased pri-miR-29b1~a expression in p53-silenced MEFs to the same extent as in p53-proficient MEFs ( Figure   2B ), indicating that Braf V600E -mediated regulation of pri-miR-29b1~a in MEFs is indeed independent of p53. To test the physiological consequence of Braf V600E -induced pri-miR-29b1~a expression, we performed a miR-29 Luciferase reporter assay in p53-silenced LSL-Braf V600E MEFs. Induction of Braf V600E decreased Luciferase activity, suggesting that the extent of miR-29b1~a upregulation is sufficient for target repression ( Figure 2C ).
Given that Braf V600E -induced miR-29b1~a expression is independent of p53, we examined the involvement of the MAPK pathway downstream of oncogenic BRAF in miR-29 regulation. To this end, we treated LSL-Braf V600E MEFs with the MEK inhibitor AZD6244 (Selumetinib) with or without induction of Braf V600E . 24 hours of AZD6244 treatment decreased basal and Braf V600E -induced MAPK pathway activity, as shown by reduced levels of pErk and the downstream transcriptional target c-Jun ( Figure 2D and 2E). MEK inhibition also decreased basal and Braf V600E -induced pri-miR-29b1~a expression ( Figure 2D ). This effect was also observed in p53-silenced LSL-Braf V600E MEFs ( Figure 2E ), indicating that oncogenic BRAF regulates miR-29b1~a independently of p53 via the MAPK pathway. AZD6244 treatment blunted Braf V600E -induced pri-miR-29b2~c expression, possibly due to reduced p53 expression ( Figure 2D ). Neither Braf V600E expression nor MEK inhibition affected pri-miR-29b2~c levels in the absence of p53 ( Figure 2E ). These data suggest differential regulation of the miR-29 clusters by Braf V600E in MEFs: while miR-29b1~a is controlled by the MAPK pathway, miR-29b2~c expression depends on p53.
The MAPK pathway regulates miR-29 expression in human melanocytes and melanoma cells
We next examined if the regulation of miR-29 observed in MEFs is conserved in human melanocytes and melanoma cell lines. Treatment of the immortalized human melanocyte lines Hermes1 and Hermes3A with Doxorubicin increased p53 and p21 ( Figure 3A ). This induction of p53 robustly elevated pri-miR-29b2~c levels ( Figure 3A ), indicating that p53 regulates pri-miR-29b2~c also in melanocytes. To analyze miR-29 regulation by the MAPK pathway in melanocytes we starved Hermes1 and Hermes3A cells of TPA, a phorbol ester that stimulates the MAPK pathway and that is required for melanocyte proliferation in vitro. Re-stimulation with TPA increased pERK levels and pri-miR-29b1~a expression ( Figure 3B ). Interestingly, TPA also moderately enhanced pri-miR-29b2~c expression ( Figure 3B ). Further, MEK inhibition with AZD6244 in Hermes1 and Hermes3A cells cultured in the presence of TPA diminished the expression of pri-miR-29b1~a and pri-miR-29b2~c ( Figure 3C ). Moreover, AZD6244 also decreased the levels of pri-miR-29b1~a and pri-miR-29b2~c in A375 and WM164 human melanoma cell lines ( Figure 3D ). Thus, while p53 potently stimulates miR-9 29b2~c in both MEFs and melanocytes, the MAPK pathway induces expression of both miR-29 clusters in cells of the melanocytic lineage.
Our results indicate that Braf V600E -induced expression of miR-29 may form a tumor suppressive barrier that restricts the full transformation of melanocytes. Thus, to analyze pri-miR-29 expression during melanomagenesis we performed RNA sequencing on four wildtype BRAF human melanocyte cell lines (Hermes1, Hermes2, Hermes3A, and Hermes4B) and five human melanoma cell lines (WM35, 1205Lu, WM164, SKMel28 and WM793) harboring the oncogenic BRAF V600E mutation. In addition, we interrogated pri-miR-29 expression in a publicly available RNAseq dataset (Kunz et al. 2018) containing 23 nevi and 57 primary melanomas. In agreement with our observations, we found that there was a trend towards increased pri-miR-29b1~a expression in melanoma cell lines and primary melanomas compared to melanocyte cell lines and nevi, respectively ( Figure 3E and 3F). Notably, expression of pri-miR-29b2~c was attenuated in melanoma cell lines and primary melanomas ( Figure 3E and 3F), suggesting that a reduction of miR-29b and/or miR-29c is associated with melanoma progression.
To further analyze miR-29 regulation during melanocyte transformation, we examined the consequences of chronic BRAF V600E expression in human melanocytes. We delivered lentiviral HA-tagged BRAF V600E to Hermes1 and Hermes3A cells, which resulted in the emergence of four independent clones, one from Hermes1 (H1B) and three from Hermes3A (H3B2, H3B4 and H3B8). These cell lines are morphologically different from the parental lines, express ectopic BRAF V600E , and exhibit increased MAPK signaling as shown by elevated pERK and c-Jun ( Supplementary Figure 2A and 2B), which enables these cells to proliferate in the absence of TPA (Supplementary Figure 2C and 2D) .
Notably, all four cell lines lost expression of p53 ( Supplementary Figure 2A and 2B), and RNA sequencing revealed that similar to melanoma cell lines and primary melanomas, H1B cells exhibited reduced pri-miR-29b2~c expression and a trend towards increased pri-miR-29b1~a levels ( Figure 3G ). Finally, expression of both pri-miR-29b1~a and pri-miR-29b2~c was sensitive to AZD6244 treatment in H1B and H3B8 cells ( Figure 3H ).
These observations indicate that while MAPK signaling enhances transcription of miR-29b1~a in melanocytes, miR-29b2~c is regulated by the MAPK pathway and p53.
Furthermore, melanoma progression is associated with decreased pri-miR-29b2~c levels, possibly through impaired p53 activity.
miR-29 inactivation promotes melanoma progression
To examine the role of miR-29 in melanoma formation in vivo, we first tested a miRNA sponge approach to inactivate miR-29 in vitro. To this end, we either transfected A375 melanoma cells with a hairpin inhibitor of miR-29a, which is upregulated in melanoma cells ( Figure 3E ), or delivered a lentiviral bulged miR-29 sponge construct. While inhibition of miR-29 enhanced only the focus formation capacity of A375 cells ( Figure   4A ), the miR-29 sponge construct increased proliferation and focus formation ( Figure   4B and 4C). In addition, the miR-29 sponge increased the activity of a miR-29 Luciferase reporter ( Figure 4D ), indicating that this approach could be used in combination with our rapid melanoma mouse modeling platform (Bok et al. 2019) to assess continuous miR-29 inactivation in vivo. Embryonic stem cell (ESC)-derived chimeras produced by this approach are topically treated with 4OH-Tamoxifen (4-OHT) to activate melanocyte-specific Cre, which induces Braf V600E expression and heterozygous Pten deletion ( Figure 4E ), thereby initiating melanomagenesis. Cre also induces reverse transactivator (rtTA3) expression, enabling melanocyte-specific expression of transgenes upon Doxycycline administration ( Figure 4E ). We targeted ESCs with a Doxycycline (Dox)-inducible, GFP-linked miR-29 sponge allele or GFP as a control and produced miR-29 sponge and GFP control chimeras having similar ESC contribution.
Notably, chimeras expressing the miR-29 sponge developed melanoma faster ( Figure   4F ) and exhibited reduced overall survival ( Figure 4G ), indicating that inactivation of miR-29 accelerates melanoma development.
Melanoma cells are addicted to high levels of miR-29 target genes
We derived a melanoma cell line from a miR-29 sponge chimera to validate the functionality of the miR-29 sponge in mice and to examine the effects of restoring miR-29 activity. Withdrawing Dox from the melanoma cell line turned off miR-29 sponge expression and enhanced repression of a miR-29 Luciferase reporter ( Figure 5A ), confirming that the sponge inactivated endogenous miR-29. Moreover, Dox withdrawal reduced proliferation ( Figure 5B ) and colony formation ( Figure 5C ) of the miR-29 sponge melanoma cells, indicating that continued miR-29 inactivation, and thus miR-29 target overexpression, is required to maintain the transformed state. miR-29 may elicit its tumor suppressive potential by repressing targets such as AKT3, DNMT3A/B, or MCL1 (Mott et al. 2007; Nguyen et al. 2011; Ugalde et al. 2011; Wei et al. 2013 ); however, miR-29 hairpin inhibitors failed to increase the expression of these validated targets in A375 melanoma cells (Supplementary Figure 3A) . Thus, alternative miR-29 targets must be responsible for the effect of miR-29 hairpins on A375 focus formation ( Figure 4A ). To identify miR-29 targets with relevance to melanoma progression, we transfected A375 cells with miR-29a mimics and performed RNA sequencing. Genes that were reduced in response to miR-29a mimics were further prioritized based on three criteria: 1) the presence of predicted high-confidence miR-29 binding sites, 2) increased expression in primary melanoma compared to nevi in the GSE112509 dataset, and 3) a negative correlation in expression with pri-miR-29b2~c in the GSE112509 dataset (Supplementary Figure 3B ). This analysis yielded 9 candidate target genes: KCTD5, MYBL2, SLC31A1, MAFG, RCC2, TUBB2A, SH3BP5L, SMS, and NCKAP5L ( Figure 5D and 5E and Supplementary Figure 3C and 3D). Notably, high expression of these 9 putative miR-29 targets is associated with poorer survival of melanoma patients ( Figure 5F ), implicating these miR-29 targets in melanoma progression.
The miR-29 target MAFG promotes the transformed state in melanoma
The finding that miR-29 restoration impairs melanoma cell growth ( Figure 5B and 5C) suggests that the identified miR-29 targets could have oncogenic potential in melanoma.
We selected MAFG ( Figure 5D and 5E) for this further analysis because MAFG has been implicated in melanoma as an epigenetic regulator and transcriptional repressor (Fang et al. 2016 ). In addition, phosphorylation by ERK promotes MAFG protein stability (Fang et al. 2016 ), suggesting that hyperactive MAPK signaling could increase MAFG levels in melanoma. To first validate MAFG as a target of miR-29 we transfected miR-29a, miR-29b, or miR-29c mimics into BRAF V600E -expressing melanocytes (H1B), and melanoma cells (WM164). We observed a general reduction of MAFG mRNA and protein expression ( Figure 6A and 6B). By contrast, hairpin inhibitors of miR-29a, miR-29b, or miR-29c increased MAFG mRNA and protein levels in these cell lines ( Figure 6A and 6B).
Next, we created a MAFG 3'UTR Luciferase reporter and mutated the seed sequence of the miR-29 binding site with the highest prediction score (Supplementary Figure 4A ).
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Co-transfection of miR-29 inhibitor with the wildtype MAFG 3'UTR reporter into H1B, H3B8, A375, and WM164 cells increased Luciferase activity ( Figure 6C and Supplementary Figure 4B ). By contrast, miR-29 mimics reduced the activity of the wildtype MAFG 3'UTR reporter and this effect was partially rescued by the miR-29 binding site mutation ( Figure 6D and Supplementary Figure 4C ). These findings indicate that MAFG is a bona fide target of miR-29.
We next assessed whether MAFG plays a role in melanoma development. First, we analyzed MAFG expression in melanocytes and melanoma cell lines and found that MAFG mRNA levels are increased in melanoma cell lines ( Figure 6E ). This finding corroborates the increase in MAFG mRNA observed in primary melanomas compared to nevi ( Figure 5E ). MAFG protein expression was similarly elevated in melanoma cell lines compared to melanocytes ( Figure 6F and 6G). TPA treatment increased MAFG protein expression in Hermes1 and Hermes3A cells ( Figure 6H ), which can be attributed to ERK-mediated MAFG stability (Fang et al. 2016) . Interestingly, MAFG protein levels are further increased in BRAF V600E -expressing Hermes cells in which p53 is lost and pri-miR-29b2~c is reduced ( Figure 6H ), suggesting gradual MAFG elevation during melanoma progression. Next, we examined the effects of modulating MAFG expression on melanocytes and melanoma cells. Stable overexpression of lentiviral MAFG in Hermes1 melanocytes increased proliferation ( Figure 7A ) and conferred the ability to form colonies ( Figure 7B ). Conversely, silencing of MAFG in A375 and WM164 melanoma cells with a siRNA pool to reduce off-target effects markedly attenuated proliferation ( Figure 7C and 7E) and colony formation ( Figure 7D and 7F), indicating that MAFG has oncogenic potential and is required for the growth of melanoma cells.
DISCUSSION
Deregulation of miRNAs frequently occurs in cancer and is thought to play critical roles in all aspects of tumorigenesis. Here, we investigated the deregulation of miR-29, a miRNA with tumor suppressive properties in various cancer types (reviewed in (Alizadeh et al. 2019 Previous studies have shown that p53 regulates the expression of both miR-29b1~a and miR-29b2~c (Ugalde et al. 2011; Chen et al. 2018 ). However, our results indicate that transcription of miR-29b1~a is independent of p53, both in MEFs and in melanocytes.
Rather, miR-29b1~a is regulated directly via MAPK signaling. This discrepancy is likely due to the fact that mature miR-29 species were analyzed by qRT-PCR in the previous studies, a method that failed to distinguish mature miR-29 family members, as has been suggested previously (Kurinna et al. 2014) . Several studies have shown cluster-specific regulation of miR-29: NRF2 regulates miR-29b1~a in keratinocytes (Kurinna et al. 2014 ) and Gli and NF-B promote miR-29b1~a expression in cholangiocarcinoma cells (Mott et al. 2010) , while Myc represses expression of both miR-29b1~a and miR-29b2~c in B-cell lymphoma (Chang et al. 2008; Zhang et al. 2012a ). Thus, each of the two miR-29 clusters is regulated by a distinct repertoire of cancer-associated pathways.
Further studies into the regulation of miR-29 ought to include measurements of the primary miR-29 transcripts to avoid ambiguous results stemming from detecting mature miR-29 with low-specificity qRT-PCR methods.
Interestingly, while MAPK signaling promotes expression of only miR-29b1~a in MEFs, the MAPK pathway induces transcription of both clusters in human melanocytes. It is possible that the regulation of miR-29b2~c is not conserved between mouse and human or that miR-29b2~c expression is controlled in a cell type-specific manner. Moreover, the induction miR-29b2~c by MAPK signaling in melanocytes was much more modest than by p53 activation. It remains to be investigated how MAPK signaling and p53 activation coordinately enhance miR-29b2~c expression upon acquisition of an oncogenic BRAF mutation. p53 may be induced by oncogene-activated MAPK pathway hyperactivation as ERK has been reported to phosphorylate p53 at serine 15 (Wu 2004) .
Moreover, MAPK activation increases expression of Cyclin D, which releases E2F-1 via RB phosphorylation, thereby promoting p14ARF transcription (Peeper et al. 1997; Bates et al. 1998 ). p14ARF in turn stabilizes p53 through inhibition of MDM2 (Sherr and Weber 2000) . MAPK hyperactivation downstream of oncogenic BRAF is a critical driver of melanoma development (Davies et al. 2002) , and p53 activation in response to mutant BRAF has been observed in melanocytes (Yu et al. 2009; Ko et al. 2019) . Thus, oncogenic BRAF may activate p53 in melanocytes via the MAPK pathway, which in turn induces pri-miR-29b2~c expression. Alternatively, MAPK signaling may directly promote pri-miR-29b2~c expression, and p53 serves as a critical permissive factor that is required for pri-miR-29b2~c transcription. Oncogenic BRAF only very moderately activates p53 (Lloyd et al. 1997; Sheu et al. 2012 ), suggesting that BRAF may indeed work in concert with rather than through p53.
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Numerous reports describe tumor suppressive functions of miR-29 in cultured cells, including in melanoma cell lines (Nguyen et al. 2011; Yu et al. 2014; Cui et al. 2015; Nishikawa et al. 2015; Chen et al. 2018; Xiong et al. 2018 ), which we corroborated in our study. Given the tumor suppressive functions of miR-29 and its regulation by MAPK signaling, we hypothesized that MAPK hyperactivation could provoke a miR-29dependent barrier that prevents melanoma formation. The MAPK pathway is almost universally hyperactivated in melanoma, owing to the frequent activating mutations in BRAF and NRAS (Davies et al. 2002; Satyamoorthy et al. 2003; Gray-Schopfer et al. 2005; Sumimoto et al. 2006) . Notably, growth arrested nevi are common in humans and >80% of nevi harbor BRAF V600E mutations (Wu et al. 2007; Yeh et al. 2013 ), suggesting that such a barrier indeed exists (Michaloglou et al. 2005) . To overcome this barrier, BRAF/NRAS mutant melanocytes must reverse the increase in miR-29 levels. We observed that miR-29b2~c expression is decreased in i) melanocytes upon chronic expression of BRAF V600E , which also provoked loss of p53, ii) melanoma cell lines compared to melanocytes, and iii) primary melanomas compared to nevi. It is tempting to speculate that while miR-29b1~a remains elevated due to continuous MAPK hyperactivation, impaired p53 activity leads to decreased miR-29b2~c expression, thereby promoting melanoma progression. p53 may play a role in the growth arrest of nevi (Gray-Schopfer et al. 2006; Yu et al. 2009; Terzian et al. 2010) , and p53 inactivation in genetically engineered mice promotes melanoma development in the context of BRAF V600E (Viros et al. 2014) . Moreover, p53 mutations and copy number losses occur frequently in cutaneous melanoma (Berger et al. 2012; Hodis et al. 2012; Krauthammer et al. 2012; Krauthammer et al. 2015; Zhang et al. 2016) . Even more common are deletions of CDKN2A Krauthammer et al. 2012; Krauthammer et al. 2015; Zhang et al. 2016) , which besides p16INK4A encodes ARF, a positive regulator of p53 protein stability. A p16INK4A-independent role for ARF in melanoma suppression has been described (Hewitt et al. 2002; Sharpless et al. 2003; Freedberg et al. 2008) .
Additionally, a subset of melanomas harbor amplifications of MDM2 (Muthusamy et al. 2006; Cancer Genome Atlas 2015) , an E3 ubiquitin ligase that promotes the turnover of p53. Thus, multiple mechanisms of p53 inactivation occur in melanoma, all of which could lead to a reduction in miR-29b2~c expression.
Using a high-throughput mouse modeling approach, we inactivated miR-29 through expression of a sponge construct specifically in Braf V600E ; Pten Δ/+ melanocytes. In agreement with our hypothesis, miR-29 inactivation accelerated the development of melanoma. Not only is this the first model used to study miR-29 inactivation in tumorigenesis, our approach also affirms that synthetic miRNA sponges are powerful tools to examine miRNA function in vivo. One advantage over traditional modeling approaches, such as the previously published conditional knock-out allele of miR-29b1~a (Kogure et al. 2012) , is that a miRNA sponge has the potential to inactivate all members of a miRNA family. However, it is usually not clear how well a sponge interacts with each family member, especially in cases like the miR-29 family where one member, miR-29b, also localizes to the nucleus (Hwang et al. 2007) . Thus, future studies using alternative approaches such as CRISPR/Cas9-mediated specific deletion of individual clusters or miRNAs will further elucidate the role of each miR-29 family member in melanoma. This will also address if a decrease in miR-29b2~c in melanoma simply lowers the overall miR-29 levels to promote melanoma, indicative of functional redundancy of miR-29a, -29b, and -29c, or if miR-29b and/or miR-29c have specific functions that are impaired upon miR-29b2~c downregulation.
Since we did not observe changes in the expression of the validated miR-29 targets AKT3, MCL1, and DNMT3B, we identified new targets that might constitute vulnerabilities of melanoma. Of the 9 genes identified by our approach (KCTD5, MYBL2, SLC31A1, MAFG, RCC2, TUBB2A, SH3BP5L, SMS and NCKAP5L), RCC2, MYBL2 and SLC31A1 have previously been identified as miR-29 targets (Martinez et al. 2011; Matsuo et al. 2013; Wu et al. 2013; Hu et al. 2014; Sun et al. 2018) . We selected MAFG for further analyses because the protein is stabilized by ERK-mediated phosphorylation (Fang et al. 2016 ), suggesting that MAPK signaling converges on MAFG via ERK and miR-29. In addition to being repressed by miR-29, TCGA data indicate copy number gains of MAFG in melanoma. Thus, MAFG is deregulated in melanoma through multiple mechanisms, and our in vitro data further suggest that MAFG plays an important role in melanoma progression and maintenance. Oncogenic roles for MAFG have so far been described in lung, ovarian, colorectal, and liver cancer (Fang et al. 2016; Vera et al. 2017; Liu et al. 2018) , and, interestingly, MAFG is a binding partner of CNC and BACH protein families, including NRF2 (reviewed in (Katsuoka and Yamamoto 2016) ). NRF2 is a critical regulator of redox biology and cellular metabolism (Hirotsu et al. 2012; Hayes and Dinkova-Kostova 2014) , and mutations in NRF2 and its negative regulator KEAP1 occur frequently in lung and upper airway cancers (Cloer et al. 2019) . By contrast, mutations in NRF2/KEAP1 are rarely observed in melanoma. Future studies will address if MAFG's functions in melanoma require binding to and enhancing of the transcriptional activity of NRF2, or if other binding partners are critical. Thus, our work has uncovered that miR-29 prevents melanoma progression downstream of MAPK signaling by repressing MAFG.
MATERIALS AND METHODS
Cell culture and treatments
The human immortalized melanocytes cell lines Hermes1, Hermes2, Hermes3A and Wildtype males were derived from littermate embryos that did not harbor the LSL-Braf V600E or LSL-Kras G12D alleles. To recombine floxed alleles, MEFs were infected with approximately 10 7 pfu/mL Ad5CMVCre or Ad5CMVempty adenovirus obtained from the University of Iowa Viral Vector Core. Lenti-X 293T cells were obtained from Takara and cultured in DMEM containing 10% FBS at 37˚C in a humidified atmosphere containing 5% CO2. All cells were routinely tested for mycoplasma using MycoAlert Plus (Lonza, 20 Cat # LT07-710), and human melanoma cell lines were STR authenticated by Moffitt's Molecular Genomics Core. Doxorubicin (Fisher Scientific, Cat # BP25131) was used at a final concentration of 10µM for 24 hours and AZD6244 (Selleckchem, Cat # S1008) was used at a final concentration of 0.5µM for 8 or 24 hours. # 97065-960). Samples were analyzed in triplicate using the StepOne Plus PCR system (Applied Biosystems, USA). The comparative threshold cycle method (2 -ΔΔCt ) was used to calculate the relative expression levels. snoU6 was used as endogenous control for mature miRNAs while GAPDH or β-actin were used for mRNAs and pri-miRNAs.
RNA isolation, RNAseq and quantitative RT-PCR
TaqMan Probes for expression analyses were purchased from Thermo Fisher Scientific (U6 snRNA: 001973; mouse β-actin: Mm02619580_g1; human β-ACTIN: mouse Cdkn1a:
Mm04205640_g1;
mmu-mir-29a: Mm03306859_pri; mmu-mir-29b-2:
Mm03307196_pri; mmu-mir-29c: Mm03306860; mmu-mir-29b-1; Mm03306189_pri;
hsa-mir-29a: Hs03302672_pri; hsa-mir-29c: Hs04225365_pri; hsa-miR-29a: 002112;
hsa-miR-29b: 000413; hsa-miR-29c: 000587). Primers for SYBR Green qPCR were 
RNA-sequencing
Total RNA from cells was isolated using RNA isolation kit (Qiagen) and analyzed for RIN. 
Sequencing by the Biostatistics and Bioinformatics
Site-directed mutagenesis
We used the psiCHECK2-MAFG-3'-UTR to generate the miR-29 binding site mutant. Four different miR-29 binding sites were predicted by TargetScan, one of which is highly conserved. Site-directed mutagenesis was performed using the Q5 Site-Directed Mutagenesis Kit (NEB, Cat. # E0554S) according to the manufacturer's instructions. The primers designed to introduce mutations were: Forward-5'-gactctggtgaCCTTTGACCTGTGGGTGTC-3'; Reverse-5'-gaccgcactttaCCGCTGCACAAAACCTCA-3'.
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Cell Transfection and lentiviral transduction
For miR-29 overexpression and inhibition, 100,000 cells/well were plated in 6-well plates and transfected with 150 or 50 nM of Dharmacon miRIDIAN microRNA miR-29a mimic (C-310521-07-0002), hairpin inhibitor (IH-310521-08-0002) or negative controls (CN-002000-01-05; IN-001005-01-05) using JetPrime (VWR Cat # 89129-924)
according to the manufacturer's protocol and assayed after 48 hours. For Luciferase assays, cells were plated in 96-well plates at a density of 10,000 cells/well. psiCHECK2-MAFG-3'-UTR_wildtype or psiCHECK2-MAFG-3'UTR_miR-29-mutant were cotransfected with miR-29 mimics or inhibitors, following the procedure described above.
Luminescence was assayed after 24 hours using the Dual Luciferase Assay System (Promega, Cat # E1960), according to the manufacturer's instructions. Similarly, miR-29-sponge melanoma cell lines were plated at a density of 10,000 cells/well and transfected with psiCHECK2 or psiCHECK2-miR-29 reporter following the same procedure. Luminescence was assayed after 48 hours using the Dual Luciferase Assay System. Results were normalized to the Renilla luminescence. For retroviral transductions, Lenti-X 293T cells were transfected with the retroviral vector and Eco helper plasmid at a 2:1 ratio. For lentiviral transductions, Lenti-X 293T cells were transfected with the lentiviral vector and the ∆8.2 and pMD2-VSV-G helper plasmids at a 9:8:1 ratio. Supernatants were collected 48 hours after transfection and filtered through a 0.45μm filter. Cells were plated in 6-well plates at a density of 300,000 cells/well and transduced with supernatants in the presence of 8 μg/mL Polybrene for 6 hours.
Selection was carried out by treating the cells with 10 μg/ml Blasticidin for 5 days or 1 μg/ml Puromycin for 4 days. For siRNA transfections, 100,000 cells/well were plated in 6-well plates and transfected with 25nM of ON-TARGETplus MAFG siRNA pool (Dharmacon, Cat # L-009109-00-0005) or Non-Targeting control (Cat # D-001810-10-05) using JetPrime (VWR, Cat # 89129-924) according to the manufacturer's protocol. 8 hours after transfection, cells were trypsinized and replated for cell biological assays.
Proliferation and colony formation assays
For proliferation assays, cells were plated in 96-well plates at a density of 1,000 -2,500 cells/well and harvested for five days. Cells were fixed and stained with 0.1% crystal violet (VWR, Cat # 97061-850) solution in 20% methanol for 20 minutes followed by extraction of crystal violet with 10% acetic acid. Absorbance was measured at 600 nm using a plate reader. For colony formation assays, cells were plated in 6-well plates at a density of 1,000 -2,000 cells/well and cultured for 2-3 weeks. Cells were fixed and stained with 0.1% crystal violet (VWR, Cat# 97061-850) solution in 20% methanol for 20 minutes. Colonies were quantified using Image J software.
Immunoblotting
Protein isolation was performed as previously described (Bok et al. 2019 ). 20μg of total protein were subjected to SDS-PAGE and Western blot, performed as previously described (Bok et al. 2019 
ES cell targeting, mouse generation, and ESC-GEMM experiments
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ES cell targeting and generation of chimeras was performed a described previously (Bok et al. 2019) . Melanoma development was induced in 3-4 week old chimeras using 25mg/mL 4-OH Tamoxifen as described previously (Bok et al. 2019) . Mice were fed 200mg/kg doxycycline (Envigo, Cat # TD180625) ad libitum. All animal experiments were conducted in accordance with an IACUC protocol approved by the University of South Florida. The derivation of the murine melanoma cell line from an ESC-GEMM chimera was performed as described previously (Bok et al. 2019) .
Analysis of miR-29 target expression in The Cancer Genome Atlas
We obtained mRNA expression and survival data for KCTD5, MYBL2, SLC31A1, MAFG, RCC2, TUBB2A, SH3BP5L, SMS, and NCKAP5L of 354 skin cancer melanoma tumors from The Cancer Genome Atlas (TCGA). To generate a scoring for all nine genes with equal contribution, we normalized the mRNA expression values to the average for each gene, followed by calculating the average of each gene for each patient. For survival analysis, the data was stratified for patients with high or low score according to the median (cutoff: 0.96) and overall survival was estimated according to the Kaplan-Meier method. Groups were compared by the Log Rank test.
Statistical analysis
Statistical analysis was performed using GraphPad Prism software. Survival data were compared by applying the Log-rank (Mantel-Cox) test, and all other data were analyzed with the unpaired two-tailed t-test or ordinary one-way ANOVA. A p-value below 0.05 was considered statistically significant. 
